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Sir, Bisphosphonates are drugs costing just 43p a
day that could prevent one in ten breast cancer
deaths. However, confusion over which health body
should pay for them means that many patients are
missing out on this treatment.
While commonly used to treat osteoporosis and
advanced cancer, evidence published in 2015
demonstrated their potential in early post-
menopausal breast cancer patients to reduce the
risk of the disease spreading and becoming
incurable. Adopting them routinely in this way would
save hundreds of lives each year and offer the NHS
a long-term cost saving.
However, more than a year later, the lack of
agreement — and clear guidance — on who should
fund them has led to variation in access across
England, with some clinical commissioning groups
taking on this responsibility, while others haven’t 
yet done so.
We therefore call on the health secretary to clarify
who is responsible for funding these drugs, ensuring
that all patients who could benefit are able to do so.
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